Discount checkpoint blocker aims to disrupt market

13 May 2021
checkpoint_big

New York’s Checkpoint Therapeutics (Nasdaq: CKPT) has finished enrolling patients in a registration-enabling trial of its experimental checkpoint blocker cosibelimab.

The trial evaluates the immunotherapy as an option for people with metastatic cutaneous squamous cell carcinoma (cSCC), and has a primary efficacy endpoint of confirmed objective response rate (ORR).

Checkpoint believes its candidate is a potential best-in-class PD-L1 blocker, with a unique mechanism of action which removes the suppressive effects of PD-L1 on certain anti-tumor components of the immune system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology